[Multidrug-resistant tuberculosis: current epidemiology, therapeutic regimens, new drugs].
Multidrug and extensively resistant tuberculosis are especially severe forms of the disease for which no efficacious therapy exists in many cases. All the countries in the world have registered cases, although most of them are diagnosed in resource-limited countries from Asia, Africa and South America. For adequate treatment, first- and second-line antituberculosis drugs have to be judiciously used, but the development of new drugs with full activity, good tolerability and little toxicity is urgently needed. There are some drugs in development, some of which are already available through expanded-access programs.
C
C
Gómez-Ayerbe
M J
MJ
Vivancos
Santiago Moreno, Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal - Carretera de Colmenar, Km. 9,100 - 28034 Madrid, Spain. smguillen@salud.madrid.org.
S
S
Moreno
D000995:Antitubercular Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology*
D000995:Antitubercular Agents